Provided herein are phosphates, thiophosphates, phosphonates, and phosphinates, methods of making same, and methods of using these compounds and methods for the generation of pharmaceutically relevant phosphate, phosphonate, and phosphinate analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I):

##STR00001##

including stereoisomers, salts and tautomers thereof, wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, L.sup.6, M.sup.1, M.sup.2, A, q, w and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

Disclosed are chemical entities which are compounds of formula (I):

##STR00001##

or pharmaceutically acceptable salts thereof; wherein Y, R.sup.a, R.sup.a, R.sup.b, R.sup.c, X.sub.1, X.sub.2, X.sub.3, R.sup.d, Z.sub.1, and Z.sub.2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

The present disclosure relates to display technologies, and particularly discloses an organic electroluminescent device. This organic electroluminescent device includes a light-emitting layer, the light-emitting includes an exciplex composed of a donor molecule and an acceptor molecule, and a wide band gap material for increasing the inter-molecular spacing between the donor molecule and the acceptor molecule. According to the device of the present disclosure, the degree of orbital overlap of HOMO and LUMO of the formed exciplex and the singlet-triplet energy level difference can be reduced, the reverse intersystem crossing rate (K.sub.RISC) of the exciplex host can be increased, the Fster energy transferred to the guest molecule can be enhanced, and the efficiency and the lifetime of the device can be improved.

An alkoxy amine compound is provided, which has a chemical structure of:

##STR00001##

wherein each of R.sup.1 is independently H, C.sub.1-6 alkyl group, or C.sub.1-6 alkoxy group; R.sup.2 is C.sub.1-6 alkyl group, R.sup.3 is (C.sub.xH.sub.2x)OH or (C.sub.xH.sub.2x+1), and x is 1 to 8; R.sup.4 is H or C.sub.1-6 alkyl group; R.sup.5 is

##STR00002##

and R.sup.6 is H or C.sub.1-8 alkyl group; R.sup.7 is H or C.sub.1-6 alkyl group, R.sup.8 is

##STR00003##

Ini is a residual group of a radical initiator; and n is an integer of 1 to 10000.

Provided herein are heterocyclic compounds and pharmaceutical formulations that can be used to treat bacterial infections. Also provided herein are methods of making and using the heterocyclic compounds and pharmaceutical formulations.

Described herein are .sup.9-THC prodrugs, methods of making .sup.9-THC prodrugs, formulations comprising .sup.9-THC prodrugs and methods of using .sup.9-THC. One embodiment described herein relates to the transdermal administration of a .sup.9-THC prodrug for treating and preventing diseases and/or disorders.

The present invention relates to chromen-4-one derivatives comprising a phosphonium quaternary group, and to associated multi-salts, solvates, prodrugs and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of cancer.